Michail Ampeliotis

Michail Ampeliotis

Auto-generated profile, based on publicly available information

Michail Ampeliotis

Cardiology Department, General Hospital of Chios ''Skylitseion'', Greece

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2023 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
AKAthanasios Kartalis
Athanasios Kartalis
DADimitrios Afendoulis
Dimitrios Afendoulis
Matthaios DidagelosMatthaios Didagelos
Matthaios Didagelos
MAMichail Ampeliotis
Michail Ampeliotis
MMMaria Moutafi
Maria Moutafi
CVCharalambos Vlachopoulos
Charalambos Vlachopoulos
Chios Mastiha essential oil (CMO) is a natural product extracted from the resin of Mastiha, possessing antioxidant, anti-microbial, anti-ulcer, anti-neoplasmatic and cholesterol lowering capabilities in vitro, and its hypolipidemic effect was confirmed in animal studies. Yet, there are no randomized, placebo-controlled clinical studies in the literature regarding CMO's hypolipidemic effects in humans. A prospective, randomized, placebo-controlled study was designed to study the hypolipidemic effect of CMO capsules on healthy volunteers with elevated cholesterol. 192 healthy volunteers were screened and 160 of them with total cholesterol> 200 mg/dl participated in the study. They were randomized with a 2:1 ratio of receiving CMO capsules (200 mg mastiha-oil/capsule) and placebo for 8 weeks respectively. 113 patients received CMO and 47 were randomized in the control group, and all of them completed the follow-up period. After 8 weeks of CMO administration, total and LDL cholesterol were significantly lower in the CMO compared to the placebo group 215.2±27.5 vs 237.0±27.9 mg/dl (p<0.001) and 135.0±26.1 vs 153.0±23.3 mg/dl (p<0.001) respectively. No gastrointestinal adverse events, liver or renal toxicity were reported. Additionally, in the CMO group total cholesterol was significantly decreased by 20.6 mg/dl (9%) and LDL by 18.1 mg/dl (12%), triglycerides by 21.8 mg/dl (15%) and glucose by 4.6 mg/dl (5%) and HDL was increased by 2.4 mg/dl (5%), compared to their baseline values. MASTIHA-OIL study showed the efficacy and safety of CMO in reduction of Total and LDL-cholesterol after 8 weeks of administration in healthy volunteers with elevated cholesterol levels.